Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Carter

Showing results (1091-1100 of 1,189) with videos related to

Pageof 119
Sort By:
Thrombosis and Haemostasis|April 1, 2000
Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia AD H Lee, I R Walker, J Teitel, et al.
Genomics|July 1, 1997
A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancerW W He, P J Sciavolino, J Wing, et al.
The European Journal of Neuroscience|September 29, 1998
Identification and characterization of a novel member of the fibroblast growth factor familyJ M Greene, Y L Li, P A Yourey, et al.
Journal of Cosmetic Dermatology|April 14, 2026
Assessing the Utility of a Cosmetic Dermatology Journal ClubJoycie Chang, Saira Alvi, Elizabeth Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesisC Fu, S Bardhan, N D Cetateanu, et al.
Molecular Microbiology|December 30, 2015
In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterizationC D Shaw, J Lonchamp, T Downing, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 5, 1999
VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivoY Zhai, J Ni, G W Jiang, et al.
The Pharmacogenomics Journal|January 19, 2011
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatinL R Brunham, P J Lansberg, L Zhang, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 5, 2004
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profileN Aubin, P Barneoud, C Carter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinomaB I Rini, L Albiges, X Tang, et al.
Pageof 119

Showing results (1091-1100 of 1,189) with videos related to

Sort By:
Pageof 119
Thrombosis and Haemostasis|April 1, 2000
Effect of the factor V Leiden mutation on the clinical expression of severe hemophilia AD H Lee, I R Walker, J Teitel, et al.
Genomics|July 1, 1997
A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancerW W He, P J Sciavolino, J Wing, et al.
The European Journal of Neuroscience|September 29, 1998
Identification and characterization of a novel member of the fibroblast growth factor familyJ M Greene, Y L Li, P A Yourey, et al.
Journal of Cosmetic Dermatology|April 14, 2026
Assessing the Utility of a Cosmetic Dermatology Journal ClubJoycie Chang, Saira Alvi, Elizabeth Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2001
Identification of a novel membrane protein, HP59, with therapeutic potential as a target of tumor angiogenesisC Fu, S Bardhan, N D Cetateanu, et al.
Molecular Microbiology|December 30, 2015
In vitro selection of miltefosine resistance in promastigotes of Leishmania donovani from Nepal: genomic and metabolomic characterizationC D Shaw, J Lonchamp, T Downing, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|January 5, 1999
VEGI, a novel cytokine of the tumor necrosis factor family, is an angiogenesis inhibitor that suppresses the growth of colon carcinomas in vivoY Zhai, J Ni, G W Jiang, et al.
The Pharmacogenomics Journal|January 19, 2011
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatinL R Brunham, P J Lansberg, L Zhang, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 5, 2004
SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profileN Aubin, P Barneoud, C Carter, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2025
Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinomaB I Rini, L Albiges, X Tang, et al.
Pageof 119